Quest Partners LLC Buys 36,652 Shares of Catalent, Inc. (NYSE:CTLT)

Quest Partners LLC grew its stake in shares of Catalent, Inc. (NYSE:CTLT) by 289.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 49,300 shares of the company’s stock after purchasing an additional 36,652 shares during the period. Quest Partners LLC’s holdings in Catalent were worth $2,986,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Gamco Investors INC. ET AL lifted its holdings in Catalent by 403.3% in the first quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company’s stock worth $1,428,000 after buying an additional 20,273 shares during the period. UniSuper Management Pty Ltd raised its position in shares of Catalent by 509.4% in the 1st quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company’s stock worth $1,028,000 after acquiring an additional 15,217 shares in the last quarter. Swedbank AB purchased a new position in shares of Catalent in the 1st quarter valued at approximately $1,659,000. New York Life Investment Management LLC boosted its position in shares of Catalent by 67.9% during the second quarter. New York Life Investment Management LLC now owns 297,903 shares of the company’s stock valued at $16,751,000 after purchasing an additional 120,502 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Catalent by 1.1% in the first quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock worth $1,151,872,000 after purchasing an additional 218,682 shares during the period.

Catalent Stock Performance

Shares of CTLT stock opened at $59.10 on Monday. The company has a market capitalization of $10.73 billion, a price-to-earnings ratio of -26.15, a price-to-earnings-growth ratio of 2.35 and a beta of 1.16. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. Catalent, Inc. has a one year low of $36.74 and a one year high of $61.20. The company’s 50-day moving average is $59.84 and its 200 day moving average is $58.21.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the previous year, the company earned ($0.10) EPS. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. Sell-side analysts expect that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,114 shares of company stock valued at $305,931. Corporate insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

CTLT has been the subject of several recent research reports. StockNews.com raised Catalent from a “sell” rating to a “hold” rating in a research report on Thursday. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. Eight research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Catalent presently has an average rating of “Hold” and an average price target of $63.40.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.